The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of melanoma.
By enrolling patients with small metastases of melanoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of high-activity natural killer cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
Fuda cancer institute of Fuda cancer hospital
Guangzhou, Guangdong, China
Relief degree of tumors
It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）
Time frame: 3 months
Progress free survival（PFS）
Time frame: 1 year
Overall survival（OS）
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.